JP7057668B2 - 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 - Google Patents

治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 Download PDF

Info

Publication number
JP7057668B2
JP7057668B2 JP2017513004A JP2017513004A JP7057668B2 JP 7057668 B2 JP7057668 B2 JP 7057668B2 JP 2017513004 A JP2017513004 A JP 2017513004A JP 2017513004 A JP2017513004 A JP 2017513004A JP 7057668 B2 JP7057668 B2 JP 7057668B2
Authority
JP
Japan
Prior art keywords
mrna
ercc1 isoform
ercc1
protein
isoform
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017513004A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017529074A5 (https=
JP2017529074A (ja
Inventor
ジーグフリート ハウフ，
イヴォヌ ボーケロー，
イエニー ヴァーグナー，
Original Assignee
アドナーゲン ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アドナーゲン ゲーエムベーハー filed Critical アドナーゲン ゲーエムベーハー
Publication of JP2017529074A publication Critical patent/JP2017529074A/ja
Publication of JP2017529074A5 publication Critical patent/JP2017529074A5/ja
Application granted granted Critical
Publication of JP7057668B2 publication Critical patent/JP7057668B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6804—Nucleic acid analysis using immunogens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2017513004A 2014-09-18 2015-09-16 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法 Active JP7057668B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14185247 2014-09-18
EP14185247.5 2014-09-18
PCT/EP2015/071170 WO2016042009A1 (en) 2014-09-18 2015-09-16 Mrna and/or protein of ercc1 isoform 3 for use in diagnosing a resistance against a therapeutic agent and method for diagnosing a resistance against a therapeutic agent using said mrna and/or protein

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020168483A Division JP2021019612A (ja) 2014-09-18 2020-10-05 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法

Publications (3)

Publication Number Publication Date
JP2017529074A JP2017529074A (ja) 2017-10-05
JP2017529074A5 JP2017529074A5 (https=) 2018-08-23
JP7057668B2 true JP7057668B2 (ja) 2022-04-20

Family

ID=51542262

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017513004A Active JP7057668B2 (ja) 2014-09-18 2015-09-16 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法
JP2020168483A Pending JP2021019612A (ja) 2014-09-18 2020-10-05 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020168483A Pending JP2021019612A (ja) 2014-09-18 2020-10-05 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法

Country Status (4)

Country Link
US (1) US20170233826A1 (https=)
EP (1) EP3194616B1 (https=)
JP (2) JP7057668B2 (https=)
WO (1) WO2016042009A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200377955A1 (en) * 2017-06-20 2020-12-03 Liquid Genomics, Inc. USE OF CELL-FREE CIRCULATING RNA (cfRNA) EXPRESSION OF PD-L1 AND ERCC1 IN PLASMA TO MONITOR RESPONSE TO THERAPY IN NSCLC
KR102780643B1 (ko) * 2020-11-04 2025-03-17 한국과학기술원 비기능성 전사체를 이용한 parp 저해제 또는 dna 손상 약물 감수성 판정방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE309393T1 (de) * 2001-09-06 2005-11-15 Adnagen Ag Verfahren zum qualitativen und/oder quantitativen nachweis von zellen
US9702875B2 (en) * 2006-03-14 2017-07-11 Institute Gustave-Roussy Expression of isoform 202 of ERCC1 for predicting response to cancer chemotherapy
EP2008102A4 (en) * 2006-04-18 2009-07-08 Wellstat Biologics Corp DETECTION OF PROTEINS IN NEOPLASTIC CELLS IN CIRCULATION
EP2233589A1 (en) * 2009-03-19 2010-09-29 Institut Gustave Roussy MSH2 and adjuvant cisplatin-based chemotherapy in non-small-cell lung cancer
JP2013504064A (ja) * 2009-09-03 2013-02-04 ザ スクリプス リサーチ インスティチュート 循環腫瘍細胞を分類する方法
TWI577389B (zh) * 2010-10-14 2017-04-11 維里德克斯有限責任公司 使用多專一性捕捉及雞尾酒檢測試劑檢測胰臟病患之循環腫瘤細胞的方法及套組

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Ｃｌｉｎｉｃａｌ Ｃｈｅｍｉｓｔｒｙ，２０１４年，Ｖｏｌ．６０，Ｎｏ．１０，ｐ．１２８２－１２８９
Ｔｈｅ Ｎｅｗ Ｅｎｇｌａｎｄ Ｊｏｕｒｎａｌ ｏｆ Ｍｅｄｉｃｉｎｅ，２０１３年，Ｖｏｌ．３６８，Ｎｏ．１２，ｐ．１１０１－１１１０

Also Published As

Publication number Publication date
EP3194616B1 (en) 2020-07-29
US20170233826A1 (en) 2017-08-17
WO2016042009A1 (en) 2016-03-24
JP2017529074A (ja) 2017-10-05
EP3194616A1 (en) 2017-07-26
JP2021019612A (ja) 2021-02-18

Similar Documents

Publication Publication Date Title
Pantel et al. Detection, clinical relevance and specific biological properties of disseminating tumour cells
Galletti et al. Circulating tumor cells in prostate cancer diagnosis and monitoring: an appraisal of clinical potential
Hudler et al. Proteomic approaches in biomarker discovery: new perspectives in cancer diagnostics
de Albuquerque et al. Multimarker analysis of circulating tumor cells in peripheral blood of metastatic breast cancer patients: a step forward in personalized medicine
Li et al. Noninvasive Diagnosis and Molecular Phenotyping of Breast Cancer through Microbead‐Assisted Flow Cytometry Detection of Tumor‐Derived Extracellular Vesicles
Chen et al. Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer
EP2449383B1 (en) Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms
JP5568807B2 (ja) プロテオミクス解析を用いたメラノーママーカーの同定
JP2021019612A (ja) 治療剤に対する抵抗性の診断に使用するためのＥＲＣＣ１アイソフォーム３のｍＲＮＡおよび／またはタンパク質ならびにこのｍＲＮＡおよび／またはタンパク質を使用する治療剤に対する抵抗性を診断するための方法
Musrap et al. Proteomic analysis of cancer and mesothelial cells reveals an increase in Mucin 5AC during ovarian cancer and peritoneal interaction
JP6192122B2 (ja) 結腸直腸癌診断および予測のためのバイオマーカー
Aufderklamm et al. XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence
US20200232039A1 (en) Adm2 gene marker for diagnosis or prognosis prediction of thyroid cancer and uses thereof
KR101297309B1 (ko) 폐암 진단용 조성물 및 폐암 진단키트
US11840734B2 (en) Method for analyzing aurka expression
JP7453284B2 (ja) 癌のバイオマーカーとしてのｐｄ－ｅｃｇｆ
EP2574929A1 (en) Marker in diagnosing prostate cancer (PC)
JP2016514248A5 (https=)
CN104531878B (zh) 一种联合lncRNA和AR3检测试剂盒及应用
US20090233295A1 (en) Trim59 directed diagnostics for neoplastic disease
EP2320235A1 (en) Marker for prostate cancer diagnosis
JP2017529074A5 (https=)
Zavarykina et al. Circulating Tumor DNA And Its Potential Applications for Assessing Effectiveness of Neoadjuvant Drug Therapy in the Breast Cancer Patients
JP2010216826A (ja) 新規腫瘍マーカーを用いた乳癌の検査方法
Ak et al. Nectin-2 and nectin-4 adhesion molecules in patients with breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180711

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180711

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190529

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190904

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191101

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191205

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200603

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201005

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20201005

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20201029

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20201030

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20201211

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20201215

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210702

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210903

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211130

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20220105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220302

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20220311

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20220407

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20220407

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220408

R150 Certificate of patent or registration of utility model

Ref document number: 7057668

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250